en · de · es
analytical-notes.peptides5388.com › Topic › Sr9009 Background And Receptor Mechanism — Beginner to Advanced

Sr9009 Background And Receptor Mechanism — Beginner to Advanced

By Editorial Desk · published 2026-07-29 · last reviewed 2026-08-01 · Topic

A practical reference on LC-MS/MS: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.

SR9009 Background and Receptor Mechanism

Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.

SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.

Background and Pharmacological Mechanism

Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.

SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.

Sr9009 at a glance

PropertyValueNotes
Chemical classSynthetic REV-ERB agonistSmall-molecule nuclear receptor ligand
AppearanceOff-white to pale yellow solidTypical for research-grade powder
Solubility classSoluble in DMSO; low water solubilityCommon stock solutions use organic solvent
Typical stock solventDimethyl sulfoxideUsed for laboratory assays
Common analytical methodHPLC with UV or mass detectionUsed for identity and purity checks

Regulation, Testing, and Storage

Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.

SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.

Related pages on this site

Further detail

=== New township development === The Government of Maharashtra has authorized MSRDC to act as the New Town Development Authority to venture into the long-term development of 19 new towns. at strategic nodes, which is also coined as 'Krushi Samruddhi Nagar.' The provisions are enacted under sub-section (1) and section 113 of the MR & TP Act, 1966. The developmental objective to propose these new towns is to encourage the self-employment potential of the regional population through their primitive occupation, i.e., agriculture or agro-related businesses. Every township developed under the initiative of Krushi Samruddhi Nagar will be built on a land area of approximately 1000-1500 hectares. The new towns shall serve as the utility economic nodes for food processing industry, integrated logistics, and domestic food markets, along with education centers, skill development institutes, healthcare facilities, and commercial and residential housings. The new townships will offer huge industrial land-banks with a focus on dedicated export-oriented infrastructure and integrated logistics to ease the supply chain with enhanced road connectivity for domestic markets. The Samruddhi Mahamarg connects 15–16 districts directly to Jawaharlal Nehru Port Trust (JNPT), reducing cargo delivery times from six to seven days to under ten hours, supporting Maharashtra's port-led growth strategy. The 19 new towns will be developed at strategic intersections, at a distance of 30 to 40 km from each other.

Drew often has issues with Berto over boundaries and the door being locked (at one point, prompting an intervention by Ryan and Amber) and because Berto slept with Natalie (while Amy was visiting Drew). When Drew returns to the room after a few weeks’ absence, Berto suggests the Drew voice his issues while chugging beer; Drew and Berto seem to get along afterwards. Natalie (Lyndon Smith) is Drew's love interest and dorm-mate at UC Berkeley during seasons 5 and 6. Chris Jefferies (Coby Ryan McLaughlin) is Julia's colleague at the law firm where she works during season 6. They dated in law school, and got back in a romantic relationship, until she reconciles with Joel. Before Julia and Joel reconcile, though, Adam recruits Chris for a basketball game during a family picnic where Chris only came to have Julia sign a paper; Joel is mad because she introduced him to the kids. Dr. Leland Gordon (Leland Crooke) is the physician who performs heart surgery on Zeek, and sees him when Zeek has a second cardiac episode. Dylan Jones (Ally Ioannides) is a newer student at Chambers Academy with ADHD and an abrupt personality, who befriends Max (whom she usually calls "Asperger's"). Max becomes romantically interested in her, but she does not reciprocate the feelings that Max has. Aaron Brownstein (Isaac Salzman) is a student at Chambers Academy with ADHD. He is in the culinary arts class, where students are always warning Adam Braverman (who teaches the class) when Aaron has matches or a knife.

==== Immunoturbidimetry ==== Immunoturbidimetry uses antibodies specific to a substance of interest to cause a measurable change in turbidity (cloudiness) of a solution. An example protocol for HbA1c measurement by immunoturbidimetry is:

Ion mobility spectrometry–mass spectrometry (IMS-MS) is an analytical chemistry method that separates gas phase ions based on their interaction with a collision gas and their masses. In the first step, the ions are separated according to their mobility through a buffer gas on a millisecond timescale using an ion mobility spectrometer. The separated ions are then introduced into a mass analyzer in a second step where their mass-to-charge ratios can be determined on a microsecond timescale. The effective separation of analytes achieved with this method makes it widely applicable in the analysis of complex samples such as in proteomics and metabolomics.

Sources: en.wikipedia.org

Background from the literature

=== Physical === Cardiovascular side effects can include hypertension or hypotension from a vasovagal response, Raynaud's phenomenon (reduced blood flow to the hands and feet), and tachycardia (increased heart rate). Sexual side effects in males may include erectile dysfunction, frequent erections, or prolonged erections. Gastrointestinal side effects may include abdominal pain, constipation, diarrhea, and nausea. Other potential physical side effects include appetite loss, blurred vision, dry mouth, excessive grinding of the teeth, nosebleed, profuse sweating, rhinitis medicamentosa (drug-induced nasal congestion), reduced seizure threshold, tics (a type of movement disorder), and weight loss. Dangerous physical side effects are rare at typical pharmaceutical doses. Amphetamine stimulates the medullary respiratory centers, producing faster and deeper breaths. In a normal person at therapeutic doses, this effect is usually not noticeable, but when respiration is already compromised, it may be evident. Amphetamine also induces contraction in the urinary bladder sphincter, the muscle which controls urination, which can result in difficulty urinating. This effect can be useful in treating bed wetting and loss of bladder control. The effects of amphetamine on the gastrointestinal tract are unpredictable. If intestinal activity is high, amphetamine may reduce gastrointestinal motility (the rate at which content moves through the digestive system); however, amphetamine may increase motility when the smooth muscle of the tract is relaxed.

Buffalo General Medical Center-Located on the Buffalo Niagara Medical Campus, Buffalo General Medical Center offers a wide spectrum of clinical inpatient and outpatient treatment programs. John R. Oishei Children's Hospital-This regional center for specialized pediatric and women's health care has achieved national recognition and is ranked among the top 20 pediatric hospitals in the nation by U.S. News & World Report. Millard Fillmore Suburban Hospital- this 200-bed community hospital supports residency training programs in anesthesiology, emergency medicine, general surgery, urology, obstetrics and gynecology, and family practice. DeGraff Memorial Hospital-A 70-bed community hospital primarily serving the needs of patients in towns north of Buffalo. Erie County Medical Center-This 550-bed medical center serves as a regional center for trauma, burns, rehabilitation and cardiac care. Veterans Affairs Western New York Healthcare System-The Buffalo VA Medical Center provides inpatient and outpatient programs. It is the main referral center for cardiac surgery, cardiology and comprehensive cancer care for Western New York and northern Pennsylvania. Sisters of Charity Hospital- Buffalo's first hospital and a Designated Stroke Center, Sisters of Charity Hospital serves patients in its inpatient and outpatient facilities. Mercy Hospital of Buffalo-Mercy Hospital is a Center of Excellence for Stroke and Cardiac Care. It recently revamped emergency department is a model for emergency health-care treatment.

The relative molecular mass (denoted Mr) of a substance, formerly also called molecular weight and abbreviated as MW, is the mass of one molecule of that substance, relative to the dalton (Da), which is equal to 1/12 the mass of one atom of 12C. Due to this relativity, the molecular mass of a substance is commonly referred to as the relative molecular mass, and denoted to Mr.

=== Legal status === In July 2017, the US Food and Drug Administration (FDA) approved guselkumab for the treatment of plaque psoriasis. In November 2017, Health Canada approved guselkumab for the treatment of plaque psoriasis. In September 2020, the approval was expanded to include the treatment of adults with psoriatic arthritis. In April 2018, guselkumab was approved in Japan for the treatment of psoriatic arthritis. In July 2020, the FDA approved guselkumab as the first IL-23 inhibitor to treat active psoriatic arthritis (PsA). In September 2024, the FDA approved guselkumab for the treatment of moderately to severely active ulcerative colitis in adults. In May 2025, the UK Medicines and Healthcare products Regulatory Agency approved guselkumab for Crohn's disease and ulcerative colitis.

CAIS is usually not suspected until the menses fail to develop at puberty, or an inguinal hernia presents during premenarche. As many as 1–2% of prepubertal girls that present with an inguinal hernia will also have CAIS. A diagnosis of CAIS or Swyer syndrome can be made in utero by comparing a karyotype obtained by amniocentesis with the external genitalia of the fetus during a prenatal ultrasound. Many infants with CAIS do not experience the normal, spontaneous neonatal testosterone surge, a fact which can be diagnostically exploited by obtaining baseline luteinizing hormone and testosterone measurements, followed by a human chorionic gonadotropin (hCG) stimulation test. The main differentials for CAIS are complete gonadal dysgenesis (Swyer syndrome) and Müllerian agenesis (Mayer-Rokitansky-Kuster-Hauser syndrome or MRKH). Both CAIS and Swyer syndrome are associated with a 46,XY karyotype, whereas MRKH is not; MRKH can thus be ruled out by checking for the presence of a Y chromosome, which can be done either by fluorescence in situ hybridization (FISH) analysis or on full karyotype. Swyer syndrome is distinguished by the presence of a uterus, poor breast development and shorter stature. The diagnosis of CAIS is confirmed when androgen receptor (AR) gene sequencing reveals a mutation, although up to 5% of individuals with CAIS do not have an AR mutation. Up until the 1990s, a CAIS diagnosis was often hidden from the affected individual, the individual's family, or both.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.

How does SR9009 work?

It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.

Is SR9009 a proven performance enhancer?

No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.

What is SR9009?

It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.

Network